Tags

Type your tag names separated by a space and hit enter

Evaluation of progression markers in the premotor phase of Parkinson's disease: the progression markers in the premotor phase study.
Neuroepidemiology. 2013; 41(3-4):174-82.N

Abstract

BACKGROUND

The clinical diagnosis of Parkinson's disease (PD) is proposed to be too late for the application of beneficial neuroprotective treatment. Thus, it is important to identify and follow individuals at risk for PD in order to gain knowledge about the prodromal course of the disease. Substantia nigra hyperechogenicity (SN+) has been confirmed as a risk factor for PD and appears promising as a predictor of PD, particularly in combination with other putative PD markers. We present the design and initial data of a 2-year longitudinal investigation of subjects proposed to be at high risk of developing PD (HRPD), compared to early PD patients and control subjects. The aim of the presented study is to monitor progression of the neurodegenerative process to motor PD.

METHODS

In total, 40 HRPD, 16 PD and 41 control individuals were recruited. The HRPD subjects had SN+ and additionally either 1 cardinal PD motor sign or 2 further risk (e.g. positive family history) or prodromal markers (e.g. hyposmia). In this cohort, motor function, olfaction, mood and blood markers will be evaluated every 6 months, complemented by a comprehensive clinical, imaging and electrophysiological assessment.

RESULTS

PD, HRPD and control subjects did not differ significantly regarding age, but the HRPD group consisted mainly of males (72.5% of HRPD subjects vs. 43.9% of controls; p = 0.013). Mean disease duration in PD patients was 31 months (range 15-56). HRPD subjects were predominantly recruited according to the occurrence of slight motor signs (HRPD 77.5%, PD 100%, p = 0.05; controls 0%, HRPD vs. controls, p < 0.017). The Unified Parkinson's Disease Rating Scale motor score (mean, range) indicated that the HRPD group (4, 0-12) had values between those of controls (0, 0-2; p < 0.017) and PD subjects (26, 9-55; p < 0.017). Among nonmotor symptoms, hyposmia was more common in both HRPD (47.5%) and PD subjects (75%) than in controls (5.1%; p < 0.017 for both comparisons).

CONCLUSIONS

Here, we describe the recruitment of a highly enriched-risk cohort and a promising study design to assess progression to motor PD. Whether the HRPD group indeed suffers from early, PD-specific neurodegeneration remains to be verified in the ongoing follow-up examinations.

Authors+Show Affiliations

Department of Neurodegeneration, Center of Neurology, Hertie Institute for Clinical Brain Research, Tübingen, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24051361

Citation

Liepelt-Scarfone, Inga, et al. "Evaluation of Progression Markers in the Premotor Phase of Parkinson's Disease: the Progression Markers in the Premotor Phase Study." Neuroepidemiology, vol. 41, no. 3-4, 2013, pp. 174-82.
Liepelt-Scarfone I, Gauss K, Maetzler W, et al. Evaluation of progression markers in the premotor phase of Parkinson's disease: the progression markers in the premotor phase study. Neuroepidemiology. 2013;41(3-4):174-82.
Liepelt-Scarfone, I., Gauss, K., Maetzler, W., Müller, K., Bormann, C., Fruhmann Berger, M., Timmers, M., Streffer, J., & Berg, D. (2013). Evaluation of progression markers in the premotor phase of Parkinson's disease: the progression markers in the premotor phase study. Neuroepidemiology, 41(3-4), 174-82. https://doi.org/10.1159/000353560
Liepelt-Scarfone I, et al. Evaluation of Progression Markers in the Premotor Phase of Parkinson's Disease: the Progression Markers in the Premotor Phase Study. Neuroepidemiology. 2013;41(3-4):174-82. PubMed PMID: 24051361.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of progression markers in the premotor phase of Parkinson's disease: the progression markers in the premotor phase study. AU - Liepelt-Scarfone,Inga, AU - Gauss,Katharina, AU - Maetzler,Walter, AU - Müller,Katharina, AU - Bormann,Christian, AU - Fruhmann Berger,Monika, AU - Timmers,Maarten, AU - Streffer,Johannes, AU - Berg,Daniela, Y1 - 2013/09/17/ PY - 2013/02/01/received PY - 2013/06/06/accepted PY - 2013/9/21/entrez PY - 2013/9/21/pubmed PY - 2014/8/16/medline SP - 174 EP - 82 JF - Neuroepidemiology JO - Neuroepidemiology VL - 41 IS - 3-4 N2 - BACKGROUND: The clinical diagnosis of Parkinson's disease (PD) is proposed to be too late for the application of beneficial neuroprotective treatment. Thus, it is important to identify and follow individuals at risk for PD in order to gain knowledge about the prodromal course of the disease. Substantia nigra hyperechogenicity (SN+) has been confirmed as a risk factor for PD and appears promising as a predictor of PD, particularly in combination with other putative PD markers. We present the design and initial data of a 2-year longitudinal investigation of subjects proposed to be at high risk of developing PD (HRPD), compared to early PD patients and control subjects. The aim of the presented study is to monitor progression of the neurodegenerative process to motor PD. METHODS: In total, 40 HRPD, 16 PD and 41 control individuals were recruited. The HRPD subjects had SN+ and additionally either 1 cardinal PD motor sign or 2 further risk (e.g. positive family history) or prodromal markers (e.g. hyposmia). In this cohort, motor function, olfaction, mood and blood markers will be evaluated every 6 months, complemented by a comprehensive clinical, imaging and electrophysiological assessment. RESULTS: PD, HRPD and control subjects did not differ significantly regarding age, but the HRPD group consisted mainly of males (72.5% of HRPD subjects vs. 43.9% of controls; p = 0.013). Mean disease duration in PD patients was 31 months (range 15-56). HRPD subjects were predominantly recruited according to the occurrence of slight motor signs (HRPD 77.5%, PD 100%, p = 0.05; controls 0%, HRPD vs. controls, p < 0.017). The Unified Parkinson's Disease Rating Scale motor score (mean, range) indicated that the HRPD group (4, 0-12) had values between those of controls (0, 0-2; p < 0.017) and PD subjects (26, 9-55; p < 0.017). Among nonmotor symptoms, hyposmia was more common in both HRPD (47.5%) and PD subjects (75%) than in controls (5.1%; p < 0.017 for both comparisons). CONCLUSIONS: Here, we describe the recruitment of a highly enriched-risk cohort and a promising study design to assess progression to motor PD. Whether the HRPD group indeed suffers from early, PD-specific neurodegeneration remains to be verified in the ongoing follow-up examinations. SN - 1423-0208 UR - https://www.unboundmedicine.com/medline/citation/24051361/Evaluation_of_progression_markers_in_the_premotor_phase_of_Parkinson's_disease:_the_progression_markers_in_the_premotor_phase_study_ L2 - https://www.karger.com?DOI=10.1159/000353560 DB - PRIME DP - Unbound Medicine ER -